Home › Polycythemia Vera › NCT07734272
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
STANDARDIZEd Documentation and Assessments for Polycythemia Vera (STANDARDIZE-PV): A Quality Improvement Initiative
Who can join
All ages · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: \- Hematologists and medical oncologists within the Mass General Brigham network sites who treat at least one patient with PV in their outpatient clinic. Exclusion Criteria: * Clinicians who do not have an outpatient hematology or medical oncology clinic within Mass General Brigham. * Clinicians who do not utilize the EPIC electronic medical record (EMR) System as their method of patient progress note documentation.
About the study
The purpose of this quality improvement initiative is to explore whether an electronic medical records-based templated progress note for polycythemia vera (PV) in addition to a standard-of-care pharmacist-collaborative ropeginterferon alfa-2b titration service is feasible, acceptable, and appropriate for clinicians who manage PV.
What is being tested
- Standardized progress note (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 32 · Started: Sep 11, 2026
Contact the study team
- Michelle Lee, MD · Phone: 617-882-6060
Official record on ClinicalTrials.gov — NCT07734272
Locations in the U.S.
| Massachusetts | Mass General Brigham Cancer Institute, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.